- Home
- ENTX vs TLSA Comparison
ENTX vs TLSA Comparison
Compare ENTX & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTX
- TLSA
- Stock Information
- Founded
- ENTX 2010
- TLSA 2013
- Country
- ENTX Israel
- TLSA United Kingdom
- Employees
- ENTX N/A
- TLSA N/A
- Industry
- ENTX Biotechnology: Biological Products (No Diagnostic Substances)
- TLSA Biotechnology: Pharmaceutical Preparations
- Sector
- ENTX Health Care
- TLSA Health Care
- Exchange
- ENTX Nasdaq
- TLSA Nasdaq
- Market Cap
- ENTX 90.2M
- TLSA 87.8M
- IPO Year
- ENTX 2018
- TLSA 2000
- Fundamental
- Price
- ENTX $2.30
- TLSA $0.68
- Analyst Decision
- ENTX Strong Buy
- TLSA
- Analyst Count
- ENTX 1
- TLSA 0
- Target Price
- ENTX $10.00
- TLSA N/A
- AVG Volume (30 Days)
- ENTX 83.9K
- TLSA 1.2M
- Earning Date
- ENTX 03-07-2025
- TLSA 02-11-2025
- Dividend Yield
- ENTX N/A
- TLSA N/A
- EPS Growth
- ENTX N/A
- TLSA N/A
- EPS
- ENTX N/A
- TLSA N/A
- Revenue
- ENTX $99,000.00
- TLSA N/A
- Revenue This Year
- ENTX N/A
- TLSA N/A
- Revenue Next Year
- ENTX N/A
- TLSA N/A
- P/E Ratio
- ENTX N/A
- TLSA N/A
- Revenue Growth
- ENTX 607.14
- TLSA N/A
- 52 Week Low
- ENTX $0.68
- TLSA $0.41
- 52 Week High
- ENTX $3.35
- TLSA $1.74
- Technical
- Relative Strength Index (RSI)
- ENTX 40.07
- TLSA 41.47
- Support Level
- ENTX $2.22
- TLSA $0.64
- Resistance Level
- ENTX $2.46
- TLSA $0.74
- Average True Range (ATR)
- ENTX 0.18
- TLSA 0.09
- MACD
- ENTX -0.05
- TLSA -0.00
- Stochastic Oscillator
- ENTX 16.07
- TLSA 12.35
About ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in the developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.